Evidence map›Paper›PMID 25545482›Full record

ArticleRetina (Philadelphia, Pa.)2015

New best1 mutations in autosomal recessive bestrophinopathy.

Adrian T Fung, Suzanne Yzer, Naomi Goldberg, Hao Wang, Michael Nissen, Alfonso Giovannini, Joanna E Merriam, Elena N Bukanova, Carolyn Cai, Lawrence A Yannuzzi and 2 more

Abstract readCase Reports
In one paragraph

Article in Retina (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Bestrophinopathy: An RPE-photoreceptor interface disease.Progress in retinal and eye research · 2017
    Review
  9. Article
  10. Article
  11. Unilateral BEST1-Associated Retinopathy.American journal of ophthalmology · 2016
    Observational
  12. Article
  13. BEST1: the Best Target for Gene and Cell Therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Review
  14. Reply: To PMID 25545482.Retina (Philadelphia, Pa.) · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Adrian T Fung*Vitreous-Retina-Macula Consultants of New York and the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Institute, New York, New York; †Department of Ophthalmology, Columbia University, New York, New York; ‡Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York; §Department of Pathology and Cell Biology, Columbia University, New York, New York; ¶Albany Medical Center, Albany, New York; **Department of Ophthalmology, Weill Cornell Medical College, New York, New York; ††Ophthalmology Section, Department of Neuroscience, Polytechnic University of Marche, Ancona, Italy; ‡‡Australian School of Advanced Medicine, Macquarie University Hospital, Sydney, Australia; and §§Save Sight Institute, University of Sydney, Sydney, Australia.
Suzanne Yzer
Naomi Goldberg
Hao Wang
Michael Nissen
Alfonso Giovannini
Joanna E Merriam
Elena N Bukanova
Carolyn Cai
Lawrence A Yannuzzi
Stephen H Tsang
Rando Allikmets

Funding

Instrumentation, Fabrication, and Design CoreP30EY019007 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Xin Zhang · 2010 to 2026
$12.9M
Therapeutic approaches for ABCA4-associated disordersR24EY019861 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALLIKMETS, RANDO L · 2011 to 2015
$7.2M
Toward mechanism- and gene-based therapies for retinal degenerationR01EY018213 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Stephen H Tsang · 2008 to 2026
$6.6M
Completing genetic analysis of the ABCA4 locusR01EY021163 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALLIKMETS, RANDO L · 2011 to 2014
$2.4M
Evaluating GWAS AMD Candidate Loci by Gene Editing in Human iPS CellsR21AG050437 · NIA · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G, MAHAJAN, VINIT B · 2015 to 2016
$431k
NEI NIH HHS P30 EY019007NEI NIH HHS R01 EY018213NEI NIH HHS R01 EY021163NEI NIH HHS R24 EY019861NIA NIH HHS R21 AG050437
6 · The paper itself

Abstract

purposeTo report the ocular phenotype in patients with autosomal recessive bestrophinopathy and carriers, and to describe novel BEST1 mutations.

methodsPatients with clinically suspected and subsequently genetically proven autosomal recessive bestrophinopathy underwent full ophthalmic examination and investigation with fundus autofluorescence imaging, spectral domain optical coherence tomography, electroretinography, and electrooculography. Mutation analysis of the BEST1 gene was performed through direct Sanger sequencing.

resultsFive affected patients from four families were identified. Mean age was 16 years (range, 6-42 years). All affected patients presented with reduced visual acuity and bilateral, hyperautofluorescent subretinal yellowish deposits within the posterior pole. Spectral domain optical coherence tomography demonstrated submacular fluid and subretinal vitelliform material in all patients. A cystoid maculopathy was seen in all but one patient. In 1 patient, the location of the vitelliform material was seen to change over a follow-up period of 3 years despite relatively stable vision. Visual acuity and fundus changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and systemic steroids. Carriers had normal ocular examinations including normal fundus autofluorescence. Three novel mutations were detected.

conclusionThree novel BEST1 mutations are described, suggesting that many deleterious variants in BEST1 resulting in haploinsufficiency are still unknown. Mutations causing autosomal recessive bestrophinopathy are mostly located outside of the exons that usually harbor vitelliform macular dystrophy-associated dominant mutations.

Indexed as

MutationAdultBestrophinsChildChloride ChannelsDNA Mutational AnalysisElectrooculographyElectroretinographyEye Diseases, HereditaryEye ProteinsFluorescein AngiographyGenes, RecessiveHumansPolymerase Chain ReactionRetinal DiseasesTomography, Optical CoherenceBEST1 protein, humanBestrophinsChloride ChannelsEye Proteins

Identifiers

PMID25545482
PMCPMC4425987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.